Cargando…

Recently developed drugs for the treatment of drug-resistant tuberculosis: a research and development case study

Two drugs with novel mechanisms of action, the diarylquinoline bedaquiline and the nitroimidazole delamanid—as well as pretomanid from the same class of drugs as delamanid—have recently become available to treat drug-resistant tuberculosis (DR-TB) after many decades of little innovation in the field...

Descripción completa

Detalles Bibliográficos
Autores principales:	Perrin, Christophe, Athersuch, Katy, Elder, Greg, Martin, Manuel, Alsalhani, Alain
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9020285/ https://www.ncbi.nlm.nih.gov/pubmed/35440441 http://dx.doi.org/10.1136/bmjgh-2021-007490

Ejemplares similares

Fostering Canadian drug research and development for neglected tropical diseases
por: Gabriel, Patricia, et al.
Publicado: (2010)

Drug resistance in malaria, tuberculosis, and HIV in South East Asia: biology, programme, and policy considerations
por: Panda, Samiran, et al.
Publicado: (2017)

Clinical challenges in the era of multiple and extensively drug-resistant tuberculosis
por: Laniado-Laborín, Rafael
Publicado: (2017)

Recent Progress and Challenges for Drug-Resistant Tuberculosis Treatment
por: Stephanie, Filia, et al.
Publicado: (2021)

Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in India
por: Moonan, Patrick K, et al.
Publicado: (2018)

Pattern of drug resistant Mycobacterium tuberculosis in the west and northwest of Iran: a meta-analysis
por: Ansarin, Khalil, et al.
Publicado: (2022)

Challenges in the development of drugs for the treatment of tuberculosis
por: Shehzad, Adeeb, et al.
Publicado: (2013)

An updated roadmap for MERS-CoV research and product development: focus on diagnostics
por: Kelly-Cirino, Cassandra, et al.
Publicado: (2019)

Recent Progress in the Development of Novel Mycobacterium Cell Wall Inhibitor to Combat Drug-Resistant Tuberculosis
por: Belete, Tafere Mulaw
Publicado: (2022)

Digital adherence technologies for the management of tuberculosis therapy: mapping the landscape and research priorities
por: Subbaraman, Ramnath, et al.
Publicado: (2018)

Metabolomics in Alcohol Research and Drug Development
por: Harrigan, George G., et al.
Publicado: (2008)

Developing a research agenda for social prescribing in the UK using lessons from the US
por: Sandhu, Sahil, et al.
Publicado: (2022)

Researches on the Development of the Bones and Teeth
Publicado: (1843)

How do psychiatric drugs work?
por: Moncrieff, Joanna, et al.
Publicado: (2009)

Fostering research into antimicrobial resistance in India
por: Das, Bhabatosh, et al.
Publicado: (2017)

Organisation of primary health care in the Asia-Pacific region: developing a prioritised research agenda
por: Palagyi, Anna, et al.
Publicado: (2019)

Trade is central to achieving the sustainable development goals: a case study of antimicrobial resistance
por: Hanefeld, Johanna, et al.
Publicado: (2017)

Development and Research Progress of Anti-Drug Resistant Bacteria Drugs
por: Cui, Xiangyi, et al.
Publicado: (2021)

Recent Advances in Multi-Drug-Resistant Tuberculosis and RNTCP
por: Grover, Gagandeep Singh, et al.
Publicado: (2008)

Metabolomics in drug research and development: The recent advances in technologies and applications
por: Pang, Huanhuan, et al.
Publicado: (2023)

Developing a globally applicable evidence-informed competency framework to support capacity strengthening in clinical research
por: Julé, Amélie, et al.
Publicado: (2017)

Researches on the Developement, Structure, and Diseases of the Teeth
Publicado: (1839)

Evaluating drug targets through human loss-of-function genetic variation
por: Minikel, Eric Vallabh, et al.
Publicado: (2020)

Developing a situation analysis tool to assess containment of antimicrobial resistance in South East Asia
por: Kakkar, Manish, et al.
Publicado: (2017)

Exposing drug industry funding of UK patient organisations
por: Ozieranski, Piotr, et al.
Publicado: (2019)

Dysregulated Metabolism in EGFR-TKI Drug Resistant Non-Small-Cell Lung Cancer: A Systematic Review
por: Babuta, Julia, et al.
Publicado: (2022)

New developments in the treatment of drug-resistant tuberculosis: clinical utility of bedaquiline and delamanid
por: Brigden, Grania, et al.
Publicado: (2015)

Pattern of Drug Resistance and Risk Factors Associated with Development of Drug Resistant Mycobacterium tuberculosis in Pakistan
por: Ullah, Irfan, et al.
Publicado: (2016)

What can we learn from drug marketing efficiency?
por: Kao, David P
Publicado: (2008)

Use of health technology assessment in drug reimbursement decisions in China
por: Chen, Wen, et al.
Publicado: (2023)

Treatment of drug-resistant tuberculosis
por: Pinto, Lancelot, et al.
Publicado: (2011)

Application of Next Generation Sequencing for Diagnosis and Clinical Management of Drug-Resistant Tuberculosis: Updates on Recent Developments in the Field
por: Dookie, Navisha, et al.
Publicado: (2022)

A systematic review on disease‐drug‐drug interactions with immunomodulating drugs: A critical appraisal of risk assessment and drug labelling
por: de Jong, Laura M., et al.
Publicado: (2022)

Risk of tuberculosis in patients with rheumatoid arthritis treated with biological and targeted drugs: meta-analysis of randomized clinical trials
por: Ji, Xiaojian, et al.
Publicado: (2022)

Tuberculosis: treatment failure, or failure to treat? Lessons from India and South Africa
por: Padayatchi, Nesri, et al.
Publicado: (2019)

Could NICE guidance on the choice of blood pressure lowering drugs be simplified?
por: Sofat, Reecha, et al.
Publicado: (2012)

Quality assurance of drugs used in clinical trials: proposal for adapting guidelines
por: Newton, Paul N, et al.
Publicado: (2015)

Managing drug shortages during a pandemic: tocilizumab and COVID-19
por: Verma, Amol A., et al.
Publicado: (2021)

Use of real world data to improve drug coverage decisions in China
por: Wang, Wen, et al.
Publicado: (2023)

Promising Lead Compounds in the Development of Potential Clinical Drug Candidate for Drug-Resistant Tuberculosis
por: Alghamdi, Saad, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uj0ugv3ktdkkvk8fei82brfpjp